Option 2:  Resverlogix can finance the Phase 3b trial internally through the sale of 50% of the future royalty stream currently owned by Zenith Capital. Funds would be used to finance BETonMACE2.

I'm not all that familiar with Zenith Capital.  Can someone flesh this out a little?  

Option 3: Resverlogix can finance and launch the Phase 3b trial with internal insider investors.

If BETonMACE2 is going to cost $150M USD, then we're looking at 50% dilution (+/- 15%), but with higher upside.  I assume we're talking about Hepalink, ORI Star and maybe 1 or 2 others?

Both of these options seem like a bit of a stretch, because RVX needed to have two other options.  So they bent over backwards to come up with something.  No?